|
ZDHHC3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.26940000014331E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.65167999999216E-05 |
| Normal-vs-Stage2 |
2.012200E-02 |
| Normal-vs-Stage3 |
1.54450000000583E-06 |
| Normal-vs-Stage4 |
1.35280009416761E-10 |
| Stage1-vs-Stage2 |
5.445000E-01 |
| Stage1-vs-Stage3 |
1.638840E-01 |
| Stage1-vs-Stage4 |
2.571100E-04 |
| Stage2-vs-Stage3 |
1.421780E-01 |
| Stage2-vs-Stage4 |
5.818600E-03 |
| Stage3-vs-Stage4 |
3.875900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.92900000031793E-07 |
| Normal-vs-AfricanAmerican |
8.404900E-03 |
| Normal-vs-Asian |
2.084600E-03 |
| Caucasian-vs-AfricanAmerican |
6.571000E-01 |
| Caucasian-vs-Asian |
5.316000E-01 |
| AfricanAmerican-vs-Asian |
9.829600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.04990000000272E-05 |
| Normal-vs-Female |
2.24939999959872E-07 |
| Male-vs-Female |
7.201000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.13870000000038E-05 |
| Normal-vs-Age(41-60Yrs) |
2.41870000028399E-07 |
| Normal-vs-Age(61-80Yrs) |
2.18149999999806E-05 |
| Normal-vs-Age(81-100Yrs) |
7.583700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.163600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.063400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.905000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.532800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.996600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.720000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.024400E-02 |
| Classical-VS-Follicular |
9.142600E-01 |
| Classical-VS-Other |
9.737600E-01 |
| Classical-VS-Normal |
2.2895999999939E-05 |
| Tall-VS-Follicular |
7.394100E-02 |
| Tall-VS-Other |
5.265600E-01 |
| Tall-VS-Normal |
4.30099999948474E-07 |
| Follicular-VS-Other |
9.943600E-01 |
| Follicular-VS-Normal |
5.443700E-04 |
| Other-VS-Normal |
2.485200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.10539999999848E-05 |
| Normal-vs-N1 |
6.67580002389201E-09 |
| N0-vs-N1 |
3.361000E-03 |
|
|
